Cathie Wood’s Ark Invest offloaded $45 million worth of Coinbase shares last week
Cathie Wood’s Ark Invest offloaded 217,305 Coinbase shares last week — valued at nearly $45 million as of market close on Friday.Ark also sold $11.4 million worth of Robinhood shares over the same period.
Investment manager Ark Invest offloaded 217,305 Coinbase shares from its Innovation exchange-traded fund (ARKK) last week, worth $44.7 million at current prices, according to the company’s latest trade filing.
Some 86,298 Coinbase shares, worth over $17 million, were sold from the fund on Wednesday alone as Ark Invest continued to rebalance its fund weightings amid the surge in COIN’s price this month. Ark also offloaded $16 million worth of Coinbase stock the week before last.
Coinbase stock traded for $205.77 at market close on Friday, up 22% for the week and 60% over the past month, according to TradingView. The stock has gained over 150% in a year but remains 40% down from an all-time high of $342.98 set during November 2021’s last crypto bull market peak.
COIN/USD price chart. Image: TradingView .
Coinbase stock hits multi-month highs despite heavy web traffic causing a temporary platform glitch
On Wednesday, COIN closed above the $200 mark for the first time since January 2022 — despite heavy web traffic causing a temporary $0 balance glitch on the crypto exchange as daily trading volume more than doubled to over $8.6 billion.
Coinbase is currently valued at $38.3 billion, according to The Block’s data dashboard .
Ark Invest sells $11.4 million worth of Robinhood shares
Ark Invest also offloaded 686,864 Robinhood shares from its Next Generation Internet (ARKW) and Fintech Innovation (ARKF) funds last week — worth around $11.4 million.
Shares in the stock and crypto trading app closed at $16.58 on Friday, gaining more than 12% for the week and 50% over the past month, per TradingView.
HOOD/USD price chart. Image: TradingView .
On Thursday, Robinhood’s self-custodial crypto wallet integrated token swaps on the Layer 2 network Arbitrum in addition to prior support for Ethereum and Polygon-based swaps.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify
In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Crypto prices
More
